A practical rule set is effective: promptly treat and stabilize DS; if inflammatory biomarkers remain elevated or BH3 profiling shows MCL-1/BCL-XL dominance, add a transient MAPK-axis partner (e.g., trametinib) or switch to a CDK9/MCL-1-directed pulse (e.g., alvocidib), then reassess dependency and MRD before escalating intensity. This evidence concerns the gene MCL1 and Dravet syndrome.